VistaGen Therapeutics, Inc. (VSTA) Management Guides Company Advancement with Broad Range of Industry Expertise

VistaGen Therapeutics has developed a versatile human pluripotent stem cell (hPSC) technology platform based on the controlled differentiation of hPSCs into mature, non-transformed, human cells. The company’s goal is to integrate this hPSC technology with modern medicinal chemistry to create a diverse drug pipeline consisting of new, proprietary, small molecule variants (Drug Rescue Variants) of once-promising drug candidates.

At the forefront of operations is CEO Shawn K. Singh, J.D., who has more than 20 years of experience working with successful public and private biotechnology and pharmaceutical companies, a life sciences venture capital firm, and a profitable contract research and development organization (CRO).

H. Ralph Snodgrass, Ph.D., founder and former CEO of VistaGen, is the company’s chief scientific officer. He has more than 18 years of experience in senior biotechnology management and, among other achievements, is a published and recognized pioneering expert in stem cell biology with more than 20 years of experience using stem cells as biological tools for drug discovery and development.

Jerrold D. Dotson provides financial direction for VistaGen as the company’s chief financial officer. His background covers a broad base of financial experience, including holding various positions in the finance and administration department of Calypte Biomedical Corp., including his last position as vice president of finance and administration and corporate secretary, California & Hawaiian Sugar Company, and The Clorox Company.

Vice president of corporate development, A. Franklin Rice, MBA, joined VistaGen in 1999. He has been employed in the biotechnology industry since 1988, previously serving as senior director of business development at Genencor International and vice president of biotechnology and pharmaceuticals for Bechtel Group where he was responsible for global sales and marketing of consulting services to biotechnology and pharmaceutical companies.

Collectively, VistaGen’s management team is advancing the company’s Human Clinical Trials in a Test Tube™ and working to strengthen the company’s presence in the lucrative biotech industry.

For more information, visit www.vistagen.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net